OAKS and DERBY Phase 3 trials: analyses of pegcetacoplan efficacy in GA due to AMD at 18 months using three different statistical models (EURETINA 2022) - Apellis Medical Hub Canada

OAKS and DERBY Phase 3 trials: analyses of pegcetacoplan efficacy in GA due to AMD at 18 months using three different statistical models

Share Via Email

Back to Conference Resources

GA Congress Presentations European Society of Retina Specialists (EURETINA) 2022

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.